{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:35:09Z","timestamp":1792017309313,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple myeloma (RRMM), eventually leading to its withdrawal from commercial use. With an imminent approval as an effective combination therapy, as seen in recent randomized trials, we report real-world clinical outcomes with belantamab mafodotin in 81 RRMM patients. With a median of 5 (range 2\u201315) prior lines of therapy, 92, 45, and 15% of the patients were triple-class refractory, penta-class refractory, and BCMA-refractory. More than half (57%) of the patients had high-risk cytogenetics, 37% had extramedullary disease (EMD), and 67% of the patients would have been considered ineligible for the DREAMM-2 trial. The best overall response (ORR) and complete response rates were 40.0 and 15.0%, respectively. ORRs were lower in patients with EMD, BCMA-refractory, and penta-refractory disease at 23, 17, and 24%, respectively. All-grade ocular toxicity was seen in 69% of patients, with grade 3+ events in 43%. Grade 3+ hematological toxicities included neutropenia (20%), anemia (28%), and thrombocytopenia (31%). With a median follow-up of 11.3 (0.3\u201344.6) months for the entire population, median PFS and OS were 5 (1\u201320) months and 12 (3\u201328) months, respectively. Presence of EMD was the only predictor of both PFS and OS on multivariable analysis. Compared to the pivotal trial and despite several high-risk disease features, belantamab mafodotin demonstrated comparable efficacy and safety in this real-world patient population.<\/jats:p>","DOI":"10.1038\/s41408-025-01226-8","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T15:13:11Z","timestamp":1741619591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6921-8086","authenticated-orcid":false,"given":"Rachel","family":"Dileo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Mewawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalaivani","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8434-2369","authenticated-orcid":false,"given":"Ethan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alkharabsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidushi","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky M, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1226_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37.","journal-title":"Blood Cancer J"},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jadpro.2022.13.1.7","volume":"13","author":"EB Ketchum","year":"2022","unstructured":"Ketchum EB, Clarke A, Clemmons AB. Belantamab mafodotin-blmf: a novel antibody-drug conjugate for treatment of patients with relapsed\/refractory multiple myeloma. J Adv Pract Oncol. 2022;13:77\u201385.","journal-title":"J Adv Pract Oncol"},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353.","journal-title":"Lancet Oncol"},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"1226_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407.","journal-title":"N Engl J Med"},{"key":"1226_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391:408\u201321.","journal-title":"N Engl J Med"},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"11829","DOI":"10.3390\/ijms241411829","volume":"24","author":"I Ntanasis-Stathopoulos","year":"2023","unstructured":"Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Roussou M, et al. Real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma. Int J Mol Sci. 2023;24:11829.","journal-title":"Int J Mol Sci"},{"key":"1226_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40487-022-00212-5","volume":"11","author":"A Alegre","year":"2023","unstructured":"Alegre A, Benzo G, Alonso R, Mart\u00ednez-L\u00f3pez J, Jimenez-Ubieto A, Cu\u00e9llar C, et al. Real-world outcomes of belantamab mafodotin for relapsed\/refractory multiple myeloma (RRMM): preliminary results of a Spanish expanded access program (EAP). Oncol Ther. 2023;11:83\u201396.","journal-title":"Oncol Ther."},{"key":"1226_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00592-3","volume":"11","author":"I Vaxman","year":"2021","unstructured":"Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, et al. \u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood Cancer J. 2021;11:196.","journal-title":"Blood Cancer J"},{"key":"1226_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.18479","volume":"200","author":"T Shragai","year":"2023","unstructured":"Shragai T, Magen H, Lavi N, Gatt M, Trestman S, Zektser M, et al. Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol. 2023;200:45\u201353.","journal-title":"Br J Haematol"},{"key":"1226_CR12","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3324\/haematol.2022.281772","volume":"108","author":"A Talbot","year":"2023","unstructured":"Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, et al. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study. Haematologica. 2023;108:2774\u201382.","journal-title":"Haematologica"},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023;129:3746\u201360.","journal-title":"Cancer"},{"key":"1226_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01081-z","volume":"14","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, et al. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14:122.","journal-title":"Blood Cancer J"},{"key":"1226_CR15","first-page":"1514","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024;109:1514\u201324.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01226-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01226-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01226-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T15:13:13Z","timestamp":1741619593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01226-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01226-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5227166\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors RD, KB, YY, EC, HS, KG, OA, AR, BP, and A-OA have no conflicts of interest to disclose. HH disclosed Janssen, Amgen, Honoraria, and Karyopharm as conflicts of interest. PM disclosed Celegene and Pfizer as conflict of interests. CS has disclosed Pfizer, Janssen, Bristol Meyer Squibb, Seagen, and Poseida as conflict of interests. JD has disclosed Janssen Biotech as a conflict of interest. NA has disclosed BMS, Kite\/Gilead, and Legend Biotech as conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. As this is a multicenter consortium study, the study was reviewed and approved by the institutional review boards (incorporating the ethics committee) at each site. As this is a multicenter consortium study utilizing retrospective data, the study was reviewed and approved by the institutional review boards (incorporating ethics committee) at each site, and the need for obtaining informed consent from the participants was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This multicenter study was a collaborative effort by US Myeloma Innovations Research Collaborative (USMIRC) and was approved by respective institutions\u2019 Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"34"}}